Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ELEVAI Labs Inc. ( (ELAB) ) has provided an announcement.
PMGC Holdings Inc. had previously entered into a License Agreement with INmune Bio, Inc. to develop, manufacture, and commercialize INmune’s EMx technology for topical cosmetic products in the medical aesthetics skincare market. On February 27, 2025, PMGC Holdings and INmune mutually terminated this agreement, with no further fees due to INmune. PMGC Holdings is considering other biotechnology assets from INmune but has not made any decisions.
More about ELEVAI Labs Inc.
YTD Price Performance: -49.80%
Average Trading Volume: 2,300,606
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.03M
Learn more about ELAB stock on TipRanks’ Stock Analysis page.